Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 5/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.38 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17320374 | 0.87 | GRM5 (0.43) | GRM5HRH3AOC3 | |
| SCHEMBL18055594 | 0.85 | HRH3 (0.42) | GRM5PARP10PARP11HRH3AOC3 | |
| SCHEMBL17313301 | 0.84 | PRMT5 (0.48) | AOC3 | |
| SCHEMBL17313304 | 0.84 | PRMT5 (0.48) | AOC3 | |
| SCHEMBL12559553 | 0.82 | PARP10 (0.44) | GRM5PARP10PARP11HRH3SRD5A1 | |
| SCHEMBL8001449 | 0.82 | GRM5 (0.48) | GRM5PARP10PARP11HRH3SRD5A1 | |
| SCHEMBL14368227 | 0.75 | GRM5 (0.48) | GRM5HRH3 | |
| SCHEMBL8002591 | 0.75 | HRH3 (0.48) | GRM5HRH3AOC3 | |
| SCHEMBL17320372 | 0.75 | GRM5 (0.45) | GRM5HRH3AOC3 | |
| SCHEMBL12559556 | 0.74 | GRM5 (0.44) | GRM5PARP10PARP11HRH3SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376387-B2 | Oxidisable pyridine derivatives, their preparation and use as anti-alzheimer agents | INSA INST NAT DES SCIENCES APPLIQUEES DE ROUEN (FR) | 2016-06-28 | — | — | US | disclosed |
| US-20150353493-A1 | OXIDISABLE PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS ANTI-ALZHEIMER AGENTS | INSA (INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE ROUEN (FR) | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353493-A1 | OXIDISABLE PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS ANTI-ALZHEIMER AGENTS | CBR3, CBR1, CYB5R3 | GRM5 1039/4885PARP10 1463/4885PARP11 2108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.